Yongqian Shu | Noncoding RNAs and Cancer Development | Excellence in Research

Prof Dr. Yongqian Shu | Noncoding RNAs and Cancer Development | Excellence in Research

The First Affiliated Hospital of Nanjing Medical University | China

Author ProfileĀ 

Orcid ID

Scopus

EARLY ACADEMIC PURSUITS

Shu Yongqian embarked on his academic journey at Suzhou Medical College, where he obtained his Bachelor's degree in Clinical Medicine in 1985. He continued his studies at the same institution, specializing in Pathology for his Master's degree under the supervision of Professor Zhou Zhen. Dr. Yongqian's dedication to his field led him to pursue a PhD in Hematology and Oncology, again at Suzhou Medical College, under the guidance of Professor Ruan Changgeng.

PROFESSIONAL ENDEAVORS

Dr. Yongqian's professional career spans over three decades, marked by significant contributions to the field of medical oncology. He began his clinical practice as a Resident Physician in the Department of Pathology at the Sino-French Friendship Hospital. Over the years, he advanced through various positions, serving as an Attending Physician and later as Deputy Chief Physician in the Oncology Department of the same institution. Currently, he holds the esteemed position of Chief Physician in the Department of Medical Oncology at the First Affiliated Hospital of Nanjing Medical University.

CONTRIBUTIONS AND RESEARCH FOCUS ON NONCODING RNAs AND CANCER DEVELOPMENT

Throughout his career, Dr. Yongqian has demonstrated a steadfast commitment to advancing knowledge in oncology. His research focuses on areas such as hematologic malignancies, solid tumors, and targeted therapies. He has authored numerous papers and contributed significantly to the understanding and treatment of various cancers.

IMPACT AND INFLUENCE

Dr. Yongqian's work has had a profound impact on the field of oncology, both locally and internationally. His research findings have been published in prestigious medical journals, contributing to the collective knowledge base of the medical community. Additionally, his clinical expertise and leadership have earned him the respect of his peers and colleagues.

ACADEMIC CITATIONS

Dr. Yongqian's contributions to the field have been recognized through academic citations, with his work being referenced by fellow researchers and clinicians worldwide. His insights and discoveries continue to shape the landscape of oncology, inspiring future generations of medical professionals.

LEGACY AND FUTURE CONTRIBUTIONS

As a seasoned clinician, researcher, and educator, Dr. Yongqian's legacy extends beyond his individual achievements. He is dedicated to training the next generation of oncologists and fostering collaboration across disciplines to further advance cancer research and patient care. His ongoing commitment to excellence ensures that his impact on the field of oncology will endure for years to come.

Notable Publications

Hongmeng Su | Gene Regulations |Ā Best Researcer Award

Dr. Hongmeng Su | Gene Regulations and Epigenetics |Ā  Best Researcer Award

Southeast University | China

Author Profile

Scopus

EARLY ACADEMIC PURSUITS

Hongmeng Su embarked on an academic journey marked by a strong foundation in bioengineering, which laid the groundwork for subsequent achievements. Graduating with a Bachelor of Engineering in Bioengineering from Nanjing Agriculture University in 2019, Su's early academic pursuits showcased a dedication to biological sciences and a burgeoning interest in research.

PROFESSIONAL ENDEAVORS

Transitioning seamlessly from undergraduate to graduate studies, Su pursued a Master of Science in Biology at the School of Life Science and Technology, Southeast University, from 2019 to 2021. This period not only honed Su's research skills but also provided a platform for academic growth and exploration in the field of biology.

CONTRIBUTIONS AND RESEARCH FOCUS ON GENE REGULATIONS AND EPIGENETICS

Su's contributions to the field of medical genetics and developmental biology are underscored by a multifaceted approach to understanding the molecular mechanisms driving hepatocellular carcinogenesis. Through meticulous research endeavors, Su has delved into the intricate interplay between non-coding RNA, transcription factors, and carcinogenesis, shedding light on key pathways implicated in cancer progression and metastasis.

IMPACT AND INFLUENCE

Su's research findings have garnered recognition and accolades, affirming the significance of their contributions to the scientific community. Notably, Su's report on the combined analysis of m6A and m5C RNA methylation modulators received honorable mention at the 10th Member Congress and Academic Seminar of Jiangsu Genetic Association, showcasing the impact of their work on hepatocellular carcinoma prognosis.

ACADEMIC CITATIONS

Su's scholarly endeavors have contributed to the advancement of knowledge in medical genetics, developmental biology, and cancer research. Their publications serve as a testament to their dedication to scientific inquiry and the dissemination of impactful findings within the academic community.

LEGACY AND FUTURE CONTRIBUTIONS

As a Ph.D. candidate at the Department of Medical Genetics & Developmental Biology, School of Medicine, Southeast University, Su's legacy is characterized by a commitment to unraveling the complexities of hepatocellular carcinogenesis. Armed with a diverse skill set encompassing molecular and cellular experimentation, bioinformatics analysis, and statistical modeling, Su is poised to make enduring contributions to the field of cancer biology and beyond. Their future endeavors hold the promise of further elucidating the molecular underpinnings of cancer progression, informing novel therapeutic strategies, and ultimately, advancing human health.

Notable Publications

TRERNA1 upregulation mediated by HBx promotes sorafenib resistance and cell proliferation in HCC via targeting NRAS by sponging miR-22-3p 2021(35)

ETV4 facilitates angiogenesis in hepatocellular carcinoma by upregulating MMP14 expression

Prognostic value of PD-L1 expression combined with hypoxia-associated immunosuppression in hepatocellular carcinoma